India Biopharma Leaders Conclave


  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

About The Summit

The Indian Pharma Market is estimated to be ~18.5 Bn USD and has the potential to grow to ~USD 80-90 Bn USD in the next 10 years

India is ranked as 10th in value and will soon be 4th, is ranked 3rd in Volume and will soon be 2nd.

Furthermore, the complications introduced by COVID-19 have had a big impact and ramifications on the overall biopharma industry.

As we are at such an important juncture of another pivotal shift in industry dynamics, it is time to look forward, review and analyze key drivers and trends that will lead India’s success and create exciting possibilities for the industry in the coming years.

Hear it from the leaders in the Indian BioPharma industry on the path forward for the sector in India.

  • The Indian Pharma Market is estimated to be ~18.5 Bn USD and has the potential to grow to ~USD 80-90 Bn USD in the next 10 years. India is ranked as 10th in value and will soon be 4th, is ranked 3rd in Volume and will soon be 2nd
  • Pharma, a well-established industry in India, combined with rising personal incomes and government healthcare outlays, is predicted to lead to annual average growth of around 16-17 per cent in the near future. Efforts to improve medical infrastructure, rising health pandemics, growing health insurance penetration and investments in research & development are amongst factors that will result in this growth.
  • Traditionally, the Indian pharmaceutical industry has focused primarily on generics as a business model, enjoying a leading position in the global generic pharmaceutical space, accounting for over 20% of global exports and nearly 80% of market share

Key Highlights

  • Key Topics of Discussion


Thought leadership and Innovation is the need of the hour as the industry looks for the next big push.


New Chemical Entities (NCEs) take a long time to develop, often at a cost of over $1billion. Conversely, the development of a supergeneric is more comparable to that of a generic compound, as it has a known mechanism of action and an established safety and efficacy profile.


Biologics and Biosimilars is expected to be the next area for growth. The first Biosimilar in India was approved in 2000 and since then almost 100 biosimilars have been approved, majority of which have come in the last 5 years.


Now, it’s more important than ever, to have a crystal clear regulatory and reimbursement framework for these newer therapies.


As the industry is changing fast, we have to make sure that we are fleet-footed when it comes to adapting to technological advancements and manufacturing methods.


Newer tools in data sciences are paving way for faster processing of information resulting in increased ability to find hidden correlations and draw insights from the data.


The pharmaceutical industry has become one of India’s largest sectors, in terms of revenue as well as employment. As the country is moving towards making itself a global leader in end-to-end discovery and innovation, the talent landscape is also strengthening.


As the industry is changing fast, we have to make sure that we are fleet-footed when it comes to adapting to technological advancements and manufacturing methods.


Pharma Business Leaders

Pharma and Biotech Research Leaders

Business Development and Sales Leaders

Pharma IT Leaders

Pharma HR Leaders

Regulatory and Govt. Affairs



Procurement Heads


Service Providers

Supply Chain


API Providers

Supply Chain

Medical Devices

Reagents and Scientific Supplies

Analytics and Consulting

Technology Companies





Regulatory Affairs

Our Partner​s

Gold Partner



Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes.
Cytiva is a global life sciences leader with over 7000 associates across 40 sites who are dedicated to our vision to improve access to life-changing therapies that transform human health. As a trusted partner to customers that range in scale and scope, Cytiva brings efficiencies to research and manufacturing workflows, ensuring the development, manufacture and delivery of transformative medicines to patients.

Industry Partner



Company Profile :
We are in the business of providing Biotech, Bio-Pharma, Fine Chemicals & Academia solutions. With state-of-the-art chromatography bulk media, resins, gels & equipment from the world’s best companies, we strive to always offer excellent technical solutions & support.
The Cellufine™ product line offers a broad range of chromatography resins for the purification of proteins, enzymes, and biomolecules. The media is based on spherical cellulose beads, and exhibits high chemical stability, mechanical strength, higher flux and is inherently bio-compatible. Applications include protein or polysaccharide purification, endotoxin removal, and is used worldwide for purifying vaccines, therapeutic enzymes, and virus concentration or purification. Cellulose media have significantly lower Leachables than comparable polymeric beads. Gel Filtration, IEX, Affinity, and HIC media available for broad range of biomolecules and applications. Cellufine customizes media, ligands or bead sizes for challenging purification process.
Besides growing and consolidating the international marketing business of industrial products and chemical specialties, we undertake forward and backword integration activity to produce tailor-made value-added specialty products.
“Our mission is to become a benchmark organization in this line of business by striving consistently to develop our organization, infrastructure & professional skills to be highly effective in this competitive environment.”

Branding Partner



“Pfanstiehl is the market leader of high purity / low endotoxin-low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all of the leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 102nd anniversary year in 2021. Pfanstiehl is headquartered at Waukegan, IL, USA and has global presence with sales offices in Switzerland for EMEA & in Singapore for APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s excipients are critical components in the majority of the top ten global blockbuster biopharmaceutical drugs which have been administered to thousands of patients around the world. Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high purity, performance, consistency and quality attributes.
For more information about Pfanstiehl and our products and solutions, please contact our business development representative for India; Mr. Aniket Chaudhari at or Mr. Hemasunder Reddy, Director – APAC at or visit

Digital Transformation Partner



TÜV SÜD is a trusted partner of choice for safety, security and sustainability solutions. We specialise in testing, certification, auditing and advisory services. Since 1866, we have remained committed to our purpose of enabling progress by protecting people, the environment and assets from technology related risks. Through more than 25,000 employees across over 1,000 locations, we add value to customers and partners by enabling market access and managing risks. By anticipating technological developments and facilitating change, TÜV SÜD inspires trust in a physical and digital world to create a safer and more sustainable future.

Networking Partner

Thermo Fisher Scientific

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit

Bronze Partner

Premas Life Sciences

Premas Life Sciences

Premas Life Sciences- Introducing cutting-edge technologies for the advancement of Biopharma/Pharma, Research and Clinical Diagnostics in India.
Incepted in 2011 by a team of highly experienced and proficient professionals, Premas Life Sciences Private Limited (PLS) is engaged in technology and knowledge distribution of proteomics, molecular biology, genetics, genomics and synthetic biology state-of-the-art niche solutions for the Indian Research and applied markets.
With the advent of the era of genomics & proteomics, leveraging the latest technology to gain an edge in mining and interpreting information has become imperative. With our ensemble range of products, we aim to provide innovative solutions to meet the ever-growing demand and over-coming the challenges of Biopharma/Pharma Industries from Drug discovery & development to QC. Our dynamic portfolio of leading global technologies boasts some of the most exciting protein sciences, synthetic biology and cell biology applications, manufactured by global giants like Codex DNA, Unchained Labs, Illumina, Fluidigm, 10X genomics, Acea Biosciences etc. which has tremendously boosted the popularity of the company.
The organization has been recognized as India’s greatest brands in the Lifescience category by Asia One. The firm can rightly boast of rare and exclusive contribution to the country’s research mechanism by providing some of the most creative and time-tested tools. Over the years, PLS’s dedicated and persistent client-centric approach has transformed this enterprise from a young start-up to an established leader with a CAGR of 60% in a very short span of time. In the quest to boost research & industrial outcomes, PLS looks forward to keep unveiling exciting technologies and develop newer markets in the Lifesciences domain.

Investment Banking Partner


Strategic Partner



BIORx Venture Advisors Private Limited (BIORx) is committed to provide the highly specialized financial and strategic advisory services. We have a proven track record of various transactional closures towards supporting superior investment growth opportunities. The company provides services in all sub-sectors of life sciences.

Our Vision Is To Enable Sustained Long Growth By Enhancing Shareholder Value By Devising Comprehensive Customized Solutions To Financial And Business Development Issues Of Our Clients.

Our Mission Is To Become The Most Preferred Financial And Strategic Partner For The Life-sciences Industry Of India.

Association Partner


Knowledge Partner


Media Partner​s

Express Pharma, today India’s leading business fortnightly for the pharmaceutical industry

Pharma Utility, a magazine dedicated to news and services in the
Indian pharmaceutical industry.

India’s most comprehensive online pharma news service. It provides updates on Indian pharma industry

IJDRA is Quarterly Open-access and peer-reviewed Journal circulated electronically and Print since 2013 .

Register Now

    For Sponsorship Opportunities :

    Register Now

      Delegates Fees

      Early Bird Fees 19,500/- + GST
      ( Valid till 16th April 2021)

      Standard Fees : Rs. 22,500/- + GST

      Register & Pay Now

      For Sponsorship Opportunities :

      Copyright @ 2020, All Rights Reserved,
      Design & Develope by